Abstract
Ribavirin and its 553 analogues have been docked with NS5-methyltransferase of Dengue viruses using Glide- HTVS and Glide-XP computational tools and the compounds have been screened based on their Glide-Gscores to identify lead ribavirin analogues that may act as inhibitors to the enzyme. Upon studying the interactions of ribavirin triphosphate (RTP) and triphosphate of lead ribavirin analogues with NS5-methyltransferase and Janus tyrosine Kinase-2 (JAK2) enzymes using molecular docking and dynamic methods, the possible mechanism by which the ribavirin causes haemolytic anaemia has been proposed. De novo RTP-analogues showing stronger affinities with NS5-methyltransferase and weaker affinities with JAK2 have been designed. The essential structural features of the de novo RTP-analogues for developing them as specific antiviral drugs against the infections due to dengue viruses have been discussed in detail.
Keywords: Drug design, glide-HTVS, JAK2, molecular docking, NS5-methyltransferase, ribavirin, haemolytic anaemia, RTP-analogues, Dengue viruses, Glide-Gsc
Medicinal Chemistry
Title: In silico Designing and Screening of Lead Compounds to NS5-Methyltransferase of Dengue Viruses
Volume: 7 Issue: 6
Author(s): Dakshinamurthy Sivakumar and Thirunavukkarasu Sivaraman
Affiliation:
Keywords: Drug design, glide-HTVS, JAK2, molecular docking, NS5-methyltransferase, ribavirin, haemolytic anaemia, RTP-analogues, Dengue viruses, Glide-Gsc
Abstract: Ribavirin and its 553 analogues have been docked with NS5-methyltransferase of Dengue viruses using Glide- HTVS and Glide-XP computational tools and the compounds have been screened based on their Glide-Gscores to identify lead ribavirin analogues that may act as inhibitors to the enzyme. Upon studying the interactions of ribavirin triphosphate (RTP) and triphosphate of lead ribavirin analogues with NS5-methyltransferase and Janus tyrosine Kinase-2 (JAK2) enzymes using molecular docking and dynamic methods, the possible mechanism by which the ribavirin causes haemolytic anaemia has been proposed. De novo RTP-analogues showing stronger affinities with NS5-methyltransferase and weaker affinities with JAK2 have been designed. The essential structural features of the de novo RTP-analogues for developing them as specific antiviral drugs against the infections due to dengue viruses have been discussed in detail.
Export Options
About this article
Cite this article as:
Sivakumar Dakshinamurthy and Sivaraman Thirunavukkarasu, In silico Designing and Screening of Lead Compounds to NS5-Methyltransferase of Dengue Viruses, Medicinal Chemistry 2011; 7 (6) . https://dx.doi.org/10.2174/157340611797928451
DOI https://dx.doi.org/10.2174/157340611797928451 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Simultaneous HPLC Determination of Metronidazole and Spiramycin in Plasma and Brain of Mouse
Current Pharmaceutical Analysis The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design The Importance of Precise Documentation of Vaccination by Physicians and Vaccine Providers
Current Drug Safety Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates
Current Gene Therapy Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
CNS & Neurological Disorders - Drug Targets Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets West Nile Virus NS2B/NS3 Protease As An Antiviral Target
Current Medicinal Chemistry Self-Organizing Maps for the Classification of Gallic Acylate Polyphenols as HSV-1 Inhibitors
Medicinal Chemistry Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Current Alzheimer Research Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science The Aftermath of Childhood Sexual Abuse: A Case Report and Review of the Literature
Adolescent Psychiatry Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Subunit Protein Vaccines: Theoretical and Practical Considerations for HIV-1
Current Molecular Medicine First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects
Current Clinical Pharmacology In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism